MCID: UTR024
MIFTS: 52

Uterine Carcinosarcoma malady

Categories: Rare diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Uterine Carcinosarcoma

Aliases & Descriptions for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 50 56 52 14 69
Malignant Mixed Müllerian Tumor of the Corpus Uteri 50 56
Mixed Müllerian Cancer of Corpus Uteri 50 56
Carcinosarcoma of the Corpus Uteri 50 56
Malignant Mixed Müllerian Tumor of Corpus Uteri 50
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:6171
NCIt 47 C42700
SNOMED-CT 64 702369008
Orphanet 56 ORPHA213610
ICD10 via Orphanet 34 C54.9
UMLS 69 C0280630

Summaries for Uterine Carcinosarcoma

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

MalaCards based summary : Uterine Carcinosarcoma, also known as malignant mixed müllerian tumor of the corpus uteri, is related to adenosarcoma and colorectal cancer, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Carboplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include uterus, lung and breast, and related phenotypes are Increased cell death HMECs cells and Increased cell viability after pRB stimulation

Related Diseases for Uterine Carcinosarcoma

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
id Related Disease Score Top Affiliating Genes
1 adenosarcoma 29.7 KIT PGR TP53
2 colorectal cancer 28.2 CTNNB1 EGFR ERBB2 ESR2 PIK3CA PTGS2
3 mouth disease 10.3 ERBB2 PGR
4 cystinosis, nephropathic 10.3 ERBB2 TP53
5 lung clear cell-sugar-tumor 10.3 ERBB2 TP53
6 glioma 10.3 ERBB2 PGR
7 mucoepidermoid thyroid carcinoma 10.3 ERBB2 PGR
8 histiocytic and dendritic cell cancer 10.2 ERBB2 PGR
9 adult central nervous system mature teratoma 10.2 ERBB2 TP53
10 aortitis 10.2 PGR TP53
11 atypical lipomatous tumor 10.2 KIT PGR
12 pericardium leiomyoma 10.2 PGR TP53
13 marfanoid hypermobility syndrome 10.2 KIT PGR
14 choriocarcinoma of ovary 10.2 KIT TP53
15 acinar cell carcinoma 10.2 PGR TP53
16 classic congenital mesoblastic nephroma 10.2 PGR TP53
17 poliomyelitis 10.2 ERBB2 PGR
18 dfnb1 10.2 CTNNB1 KIT
19 skin angiosarcoma 10.2 KIT PGR
20 porokeratosis 10.2 PGR TP53
21 liver angiosarcoma 10.2 KIT PGR
22 uterine hypoplasia 10.2 KIT PGR
23 breast pericanalicular fibroadenoma 10.2 PGR TP53
24 pineal region mature teratoma 10.2 EGFR ERBB2
25 oro-mandibular-limb hypogenesis syndrome 10.2 ERBB2 TP53
26 vulva basal cell carcinoma 10.2 KIT PGR
27 bile duct clear cell adenocarcinoma 10.2 PTGS2 TP53
28 deafness, autosomal recessive 21 10.2 ESR2 PGR
29 small intestinal l-cell glucagon-like peptide producing tumor 10.2 KIT PTGS2
30 villoglandular endometrial endometrioid adenocarcinoma 10.2 PGR TP53
31 vaginal adenosarcoma 10.2 PGR TP53
32 papilloma 10.2 CTNNB1 PGR
33 paraphimosis 10.2 PGR TP53
34 wolffian adnexal neoplasm 10.2 EGFR TP53
35 rectal neoplasm 10.2 ERBB2 KIT PGR
36 macrocytic anemia 10.1 CTNNB1 PTGS2
37 osteogenesis imperfecta 10.1 ESR2 PGR
38 central nervous system mature teratoma 10.1 ERBB2 PGR TP53
39 male reproductive organ benign neoplasm 10.1 ERBB2 PGR TP53
40 central nervous system primitive neuroectodermal neoplasm 10.1 ERBB2 PGR TP53
41 fallopian tube carcinosarcoma 10.1 ERBB2 PGR TP53
42 vulva adenocarcinoma 10.1 ERBB2 PGR TP53
43 congenital bile acid synthesis defect 10.1 ERBB2 PGR TP53
44 metagonimiasis 10.1 ERBB2 PGR TP53
45 paternal uniparental disomy of chromosome 1 10.1 EGFR TP53
46 brainstem intraparenchymal clear cell meningioma 10.1 EGFR TP53
47 mediastinum sarcoma 10.1 KIT PGR TP53
48 ovarian cystadenocarcinoma 10.1 EGFR ERBB2
49 cerebral arterial disease 10.1 CTNNB1 KIT
50 familial glucocorticoid deficiency 10.1 ERBB2 PGR TP53

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma

Symptoms & Phenotypes for Uterine Carcinosarcoma

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.35 CTNNB1 EGFR PGR PIK3CA TP53
2 Increased cell viability after pRB stimulation GR00230-A-1 8.8 EGFR ERBB2 KIT

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

44 (show all 28)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
2 cellular MP:0005384 10.28 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
3 endocrine/exocrine gland MP:0005379 10.25 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
4 behavior/neurological MP:0005386 10.23 PGR KIT PIK3CA TP53 PTGS2 CTNNB1
5 homeostasis/metabolism MP:0005376 10.22 PIK3CA PGR TP53 PTGS2 EGFR CTNNB1
6 embryo MP:0005380 10.21 PTGS2 PIK3CA PGR TP53 CTNNB1 EGFR
7 integument MP:0010771 10.2 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
8 growth/size/body region MP:0005378 10.19 KIT PIK3CA TP53 PTGS2 EGFR CTNNB1
9 digestive/alimentary MP:0005381 10.16 TP53 PTGS2 EGFR CTNNB1 ERBB2 KIT
10 immune system MP:0005387 10.16 KIT PIK3CA PGR TP53 PTGS2 EGFR
11 mortality/aging MP:0010768 10.16 KIT PIK3CA PGR TP53 PTGS2 EGFR
12 muscle MP:0005369 10.15 PIK3CA PGR PTGS2 TP53 ERBB2 EGFR
13 neoplasm MP:0002006 10.13 PIK3CA PGR PTGS2 TP53 ERBB2 EGFR
14 hematopoietic system MP:0005397 10.12 PGR KIT TP53 PTGS2 EGFR CTNNB1
15 limbs/digits/tail MP:0005371 10.08 PGR TP53 CTNNB1 EGFR KIT ESR2
16 nervous system MP:0003631 10.06 KIT PIK3CA TP53 PTGS2 EGFR CTNNB1
17 adipose tissue MP:0005375 10.04 PIK3CA TP53 PTGS2 EGFR ESR2
18 no phenotypic analysis MP:0003012 10.03 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
19 craniofacial MP:0005382 10.02 KIT TP53 EGFR CTNNB1 ERBB2
20 normal MP:0002873 10.01 PGR PTGS2 TP53 EGFR CTNNB1 KIT
21 liver/biliary system MP:0005370 10 KIT TP53 PTGS2 EGFR CTNNB1 ESR2
22 hearing/vestibular/ear MP:0005377 9.98 KIT TP53 EGFR CTNNB1 ESR2
23 reproductive system MP:0005389 9.91 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
24 renal/urinary system MP:0005367 9.8 KIT TP53 PTGS2 EGFR CTNNB1 ESR2
25 respiratory system MP:0005388 9.7 TP53 PTGS2 EGFR CTNNB1 ERBB2 KIT
26 pigmentation MP:0001186 9.67 KIT TP53 EGFR CTNNB1
27 skeleton MP:0005390 9.61 PIK3CA PGR PTGS2 TP53 EGFR CTNNB1
28 vision/eye MP:0005391 9.1 KIT PIK3CA TP53 PTGS2 EGFR CTNNB1

Drugs & Therapeutics for Uterine Carcinosarcoma

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Mechlorethamine Approved Phase 3 51-75-2 4033
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Lenograstim Approved Phase 3 135968-09-1
6
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
7
Mesna Approved Phase 3 3375-50-6 598
8
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
11
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
13 Alkylating Agents Phase 3,Phase 2
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2
16 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
17 Isophosphamide mustard Phase 3
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Anti-Allergic Agents Phase 3
22 Antipruritics Phase 3
23 Dermatologic Agents Phase 3
24 Gastrointestinal Agents Phase 3
25 Histamine Antagonists Phase 3
26 Histamine H1 Antagonists Phase 3
27
Histamine Phosphate Phase 3 51-74-1 65513
28 Neurotransmitter Agents Phase 3
29
Serotonin Phase 3 50-67-9 5202
30 Serotonin Agents Phase 3
31 Serotonin Antagonists Phase 3
32
Gemcitabine Approved Phase 2 95058-81-4 60750
33
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
38
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
39
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
40
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
41
Metformin Approved Phase 2 657-24-9 14219 4091
42
nivolumab Approved Phase 2 946414-94-4
43
Everolimus Approved Phase 2 159351-69-6 6442177
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
46
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
48
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
49
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
50
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265

Interventional clinical trials:

(show top 50) (show all 55)
id Name Status NCT ID Phase
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
2 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
7 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2
8 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
9 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2
10 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2
11 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2
12 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2
13 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2
14 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2
15 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2
16 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2
17 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
18 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
19 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
20 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
21 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2
22 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2
23 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
24 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
25 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
26 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2
27 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2
28 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
29 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2
30 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
31 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
32 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
33 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2
34 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
35 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
36 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Active, not recruiting NCT01168232 Phase 2
37 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
38 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
39 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2
40 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2
41 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2
42 Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003156 Phase 2
43 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1
44 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
45 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
46 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1
47 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Recruiting NCT01991808 Phase 1
48 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1
49 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1
50 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301

Search NIH Clinical Center for Uterine Carcinosarcoma

Genetic Tests for Uterine Carcinosarcoma

Anatomical Context for Uterine Carcinosarcoma

MalaCards organs/tissues related to Uterine Carcinosarcoma:

39
Uterus, Lung, Breast, Lymph Node, Endothelial

Publications for Uterine Carcinosarcoma

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 159)
id Title Authors Year
1
Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. ( 27931750 )
2017
2
Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. ( 28088687 )
2017
3
Uterine carcinosarcoma including angiosarcoma: A short case report. ( 27592347 )
2016
4
Prognostic impact of primary tumor SUVmax on preoperative (18)F-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography in endometrial cancer and uterine carcinosarcoma. ( 27703679 )
2016
5
Comparison of MRI and (18)F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. ( 26777990 )
2016
6
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( 27172745 )
2016
7
Unusual Cutaneous Metastasis of Uterine Carcinosarcoma: A Case Report and Review of the Literature. ( 26675357 )
2016
8
Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma. ( 27779297 )
2016
9
Utility of histogram analysis of apparent diffusion coefficient maps obtained using 3.0T MRI for distinguishing uterine carcinosarcoma from endometrial carcinoma. ( 26605502 )
2016
10
Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). ( 27550404 )
2016
11
Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic Platform. ( 27794476 )
2016
12
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. ( 27441069 )
2016
13
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. ( 26896827 )
2016
14
RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma. ( 27121792 )
2016
15
Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. ( 26941453 )
2016
16
Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. ( 27009459 )
2016
17
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. ( 27889902 )
2016
18
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. ( 27072806 )
2016
19
Prognostic value of total lesion glycolysis on preoperative (18)F-FDG PET/CT in patients with uterine carcinosarcoma. ( 26883331 )
2016
20
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. ( 27052653 )
2016
21
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. ( 26348313 )
2015
22
Clinically aggressive "low-grade" uterine carcinosarcoma: A case report. ( 26793763 )
2015
23
Role of TGF-I^ signaling in uterine carcinosarcoma. ( 25918253 )
2015
24
Azaspirene analogs inhibit the growth of human uterine carcinosarcoma in vitro and in vivo. ( 25964553 )
2015
25
Cooperation of Sox4 with I^-catenin/p300 complex in transcriptional regulation of the Slug gene during divergent sarcomatous differentiation in uterine carcinosarcoma. ( 26841870 )
2015
26
Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: A retrospective cohort study. ( 26476418 )
2015
27
Uterine carcinosarcoma: A review of the literature. ( 25805398 )
2015
28
Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. ( 25994210 )
2015
29
Evaluation of brachytherapy and external beam radiation therapy for early stage, node-negative uterine carcinosarcoma. ( 26166579 )
2015
30
Review of Recommended Treatment of Uterine Carcinosarcoma. ( 26374341 )
2015
31
The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival: A Reassessment Based on Mature Data. ( 26222488 )
2015
32
The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. ( 26509850 )
2015
33
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. ( 26254376 )
2015
34
Uterine carcinosarcoma/malignant mixed MA1llerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy. ( 26404129 )
2015
35
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. ( 26084780 )
2015
36
Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. ( 25633654 )
2015
37
URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis. ( 26328264 )
2015
38
Clinical outcomes of uterine carcinosarcoma: results of 94 patients. ( 25611900 )
2015
39
Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer (G3EC) patients: a comparative study. ( 26463439 )
2015
40
Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis. ( 26307402 )
2015
41
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. ( 25078343 )
2014
42
Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis. ( 24561247 )
2014
43
Case report of uterine carcinosarcoma with incisional site recurrence. ( 25404826 )
2014
44
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study. ( 25078338 )
2014
45
Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit. ( 25030547 )
2014
46
Pathologic prognostic factors in stage I-III uterine carcinosarcoma treated with postoperative radiotherapy. ( 24633893 )
2014
47
Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. ( 24817958 )
2014
48
Review literature on uterine carcinosarcoma. ( 25313723 )
2014
49
Black race independently predicts worse survival in uterine carcinosarcoma. ( 24613675 )
2014
50
AlloDerm graft mimicking uterine carcinosarcoma recurrence on PET/CT. ( 24359070 )
2014

Variations for Uterine Carcinosarcoma

ClinVar genetic disease variations for Uterine Carcinosarcoma:

6 (show all 42)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
12 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
13 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
23 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
24 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
25 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
26 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
27 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
28 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
29 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
30 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
31 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
32 PPP2R1A NM_014225.5(PPP2R1A): c.536C> T (p.Pro179Leu) single nucleotide variant Pathogenic/Likely pathogenic rs786205228 GRCh38 Chromosome 19, 52212718: 52212718
33 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
34 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
35 PIK3CA NM_006218.3(PIK3CA): c.1637A> C (p.Gln546Pro) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
37 PIK3CA NM_006218.3(PIK3CA): c.1637A> T (p.Gln546Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
38 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
39 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
40 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
41 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
42 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Expression for Uterine Carcinosarcoma

Search GEO for disease gene expression data for Uterine Carcinosarcoma.

Pathways for Uterine Carcinosarcoma

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 CTNNB1 EGFR ERBB2 ESR2 KIT PTGS2
2
Show member pathways
13.58 EGFR ERBB2 ESR2 KIT PTGS2 TP53
3
Show member pathways
13.22 EGFR ERBB2 KIT PIK3CA PTGS2 TP53
4
Show member pathways
13.15 CTNNB1 EGFR ERBB2 ESR2 KIT
5
Show member pathways
13 EGFR ERBB2 KIT PIK3CA TP53
6
Show member pathways
12.78 EGFR KIT PIK3CA TP53
7
Show member pathways
12.78 CTNNB1 EGFR ERBB2 PIK3CA PTGS2
8
Show member pathways
12.69 CTNNB1 EGFR ESR2 PIK3CA
9
Show member pathways
12.69 CTNNB1 ERBB2 PIK3CA PTGS2 TP53
10
Show member pathways
12.62 CTNNB1 EGFR KIT PIK3CA
11
Show member pathways
12.62 EGFR ERBB2 KIT PIK3CA TP53
12 12.49 EGFR KIT PIK3CA TP53
13
Show member pathways
12.44 CTNNB1 EGFR ERBB2 PIK3CA TP53
14
Show member pathways
12.42 EGFR ERBB2 PIK3CA TP53
15
Show member pathways
12.39 CTNNB1 EGFR ERBB2 PIK3CA TP53
16 12.31 EGFR ERBB2 PIK3CA PTGS2 TP53
17
Show member pathways
12.26 CTNNB1 KIT TP53
18
Show member pathways
12.22 EGFR ERBB2 PIK3CA TP53
19
Show member pathways
12.22 CTNNB1 EGFR ERBB2 PIK3CA TP53
20
Show member pathways
12.19 EGFR ERBB2 PIK3CA
21 12.11 CTNNB1 EGFR PTGS2 TP53
22
Show member pathways
12.1 EGFR ERBB2 TP53
23 12.1 CTNNB1 EGFR ERBB2 KIT PIK3CA PTGS2
24
Show member pathways
12.09 EGFR ERBB2 ESR2 PIK3CA PTGS2
25
Show member pathways
12.09 CTNNB1 EGFR ERBB2 KIT PIK3CA TP53
26
Show member pathways
12.08 CTNNB1 EGFR ERBB2 ESR2 KIT PGR
27 12.06 CTNNB1 EGFR TP53
28
Show member pathways
12.05 EGFR ERBB2 PIK3CA
29 12.03 CTNNB1 EGFR ERBB2 PIK3CA TP53
30 12.02 EGFR ERBB2 KIT
31
Show member pathways
12.02 CTNNB1 EGFR ERBB2 PIK3CA
32 12.01 CTNNB1 PIK3CA TP53
33 11.98 EGFR PIK3CA TP53
34
Show member pathways
11.98 EGFR ERBB2 PIK3CA TP53
35 11.93 EGFR PTGS2 TP53
36
Show member pathways
11.92 EGFR ERBB2 PIK3CA TP53
37 11.91 CTNNB1 PIK3CA TP53
38 11.89 CTNNB1 EGFR TP53
39 11.84 CTNNB1 ERBB2 PIK3CA TP53
40 11.83 EGFR ERBB2 PIK3CA
41
Show member pathways
11.8 EGFR ERBB2 KIT
42
Show member pathways
11.79 EGFR ERBB2 PGR PIK3CA
43 11.75 PIK3CA PTGS2 TP53
44 11.68 EGFR ERBB2 TP53
45 11.68 ERBB2 PIK3CA TP53
46 11.67 CTNNB1 EGFR ERBB2
47 11.63 CTNNB1 EGFR ERBB2
48 11.61 ERBB2 PIK3CA TP53
49 11.37 EGFR ERBB2 KIT PIK3CA TP53
50 11.27 CTNNB1 EGFR TP53

GO Terms for Uterine Carcinosarcoma

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 8.8 CTNNB1 EGFR ERBB2

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.92 EGFR ERBB2 KIT PIK3CA
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 CTNNB1 EGFR ESR2 TP53
3 regulation of transcription from RNA polymerase II promoter GO:0006357 9.88 CTNNB1 EGFR ERBB2 KIT
4 positive regulation of cell proliferation GO:0008284 9.84 CTNNB1 EGFR KIT PTGS2
5 cell proliferation GO:0008283 9.8 CTNNB1 EGFR ERBB2 TP53
6 protein autophosphorylation GO:0046777 9.77 EGFR ERBB2 KIT
7 peptidyl-tyrosine phosphorylation GO:0018108 9.75 EGFR ERBB2 KIT
8 positive regulation of gene expression GO:0010628 9.73 CTNNB1 ERBB2 KIT TP53
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.69 EGFR ERBB2 KIT
10 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.65 CTNNB1 ESR2 KIT
11 regulation of angiogenesis GO:0045765 9.63 CTNNB1 ERBB2
12 response to estradiol GO:0032355 9.63 CTNNB1 EGFR PTGS2
13 positive regulation of vasoconstriction GO:0045907 9.62 EGFR PTGS2
14 regulation of cell proliferation GO:0042127 9.62 CTNNB1 EGFR KIT PTGS2
15 regulation of cell motility GO:2000145 9.61 EGFR ERBB2
16 regulation of ERK1 and ERK2 cascade GO:0070372 9.6 EGFR ERBB2
17 positive regulation of MAP kinase activity GO:0043406 9.58 EGFR ERBB2 KIT
18 vasculature development GO:0001944 9.57 CTNNB1 PIK3CA
19 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.55 EGFR PTGS2
20 cellular response to growth factor stimulus GO:0071363 9.54 CTNNB1 EGFR ERBB2
21 negative regulation of ERBB signaling pathway GO:1901185 9.52 EGFR ERBB2
22 phosphatidylinositol phosphorylation GO:0046854 9.46 EGFR ERBB2 KIT PIK3CA
23 ERBB2 signaling pathway GO:0038128 9.43 EGFR ERBB2 PIK3CA
24 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.26 EGFR ERBB2 KIT PIK3CA
25 phosphatidylinositol-mediated signaling GO:0048015 9.02 EGFR ERBB2 KIT PIK3CA TP53
26 signal transduction GO:0007165 10.03 CTNNB1 EGFR ERBB2 ESR2 KIT PGR

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.71 CTNNB1 EGFR ERBB2 TP53
2 protein tyrosine kinase activity GO:0004713 9.61 EGFR ERBB2 KIT
3 protein phosphatase binding GO:0019903 9.56 CTNNB1 EGFR ERBB2 TP53
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.54 EGFR ERBB2 KIT
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 EGFR ERBB2 KIT
6 steroid binding GO:0005496 9.48 ESR2 PGR
7 disordered domain specific binding GO:0097718 9.46 CTNNB1 TP53
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 EGFR ERBB2 KIT PIK3CA
9 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.13 EGFR ERBB2 KIT
10 enzyme binding GO:0019899 9.1 CTNNB1 EGFR ESR2 PGR PTGS2 TP53

Sources for Uterine Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....